Document is current
Any future updates will be listed below
-
Authors
Everhov, Åsa H. https://orcid.org/0000-0002-0311-8894
Frisell, Thomas
Osooli, Mehdi
Brooke, Hannah L.
Carlsen, Hanne K.
Modig, Karin
Mårild, Karl
Lindström, Jonathan
Sköldin, Karin
Heurgren, Mona
Ludvigsson, Jonas F.
Olén, Ola
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (Dnr 2020-02002, 2021-01418)
Kommunfullmäktige, Stockholms Stad (ALF Dnr 20190638)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 1 September 2024
Accepted: 10 March 2025
First Online: 27 March 2025
Declarations
:
: Dr Ludvigsson has coordinated an unrelated study on behalf of the Swedish IBD quality register (SWIBREG). That study received funding from Janssen corporation. Dr Ludvigsson has also received financial support from MSD developing a paper reviewing national healthcare registers in China. Dr Ludvigsson has an ongoing research collaboration on celiac disease with Takeda. Dr Olén has been PI for academic projects about inflammatory bowel disease at Karolinska Institutet, financed by grants from Janssen, Pfizer, AbbVie, Takeda, Ferring, and Bristol Myers Squibb. Karolinska Institutet has also received fees for lectures and participation by dr Olén on advisory boards from Janssen, Ferring, Galapagos, Bristol Myer Squibb, Takeda, and Pfizer. Dr Olén also reports grants from Pfizer, AbbVie, Galapagos/Alfasigma, and Janssen in the context of national safety monitoring programs.
: Not relevant.
: Not relevant.
: Not relevant.
